Optimizing Pharmacokinetics and Pharmacodynamics of Intravenous Amikacin in Cystic Fibrosis Patients: Assessment of Clinical Outcomes and Nephrotoxicity

Update item information
Identifier 067_Huynh-Hoa_EBPF2017
Title Optimizing Pharmacokinetics and Pharmacodynamics of Intravenous Amikacin in Cystic Fibrosis Patients: Assessment of Clinical Outcomes and Nephrotoxicity
Creator Hoa Q. Huynh, PharmD, BCPS; Sílvia M. Illamola, PharmD, PhD; Xiaoxi Liu, PhD; Zubin Bhakta, PharmD; Theodore Liou, MD; Holly Carveth, MD; David C. Young, PharmD
Description Cystic fibrosis is a recessive genetic disorder caused by a mutation in the cystic fibrosis transmembrane regulator gene.
Subject Intravenous Amikacin; Cystic Fibrosis; Nephrotoxicity; Clinical Outcomes
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Date 2017
Date Digital 2017
Language eng
ARK ark:/87278/s6rj8wz6
Relation is Part of 2017 Evidence Based Practice Posters
Format application/pdf
Rights Copyright © College of Nursing, University of Utah
Setname ehsl_ebp
Date Created 2019-02-05
Date Modified 2020-05-08
ID 1399436
Reference URL https://collections.lib.utah.edu/ark:/87278/s6rj8wz6
Back to Search Results